ImmunityBio director sells 96,722 shares after option exercise
ImmunityBio, Inc. director Christobel Selecky exercised stock options and sold the resulting shares in pre-planned trades.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
ImmunityBio, Inc. director Christobel Selecky exercised stock options and sold the resulting shares in pre-planned trades. On June 29–30, 2026, she exercised options for a total of 96,722 shares of Common Stock at exercise prices between $2.84 and $2.99 per share and sold 96,722 shares in open-market transactions, including 95,722 shares at a weighted-average price of $9.0075 and 1,000 shares at $9.00 per share.
The sales were made under a Rule 10b5-1 trading plan adopted on March 13, 2026, indicating they were pre-scheduled rather than discretionary. Following these transactions, Selecky reported no directly held Common Stock, while retaining stock options to purchase additional shares at the disclosed exercise prices and expiration dates.
Insider Trade Summary 10b5-1
Exercise and Sale: 96,722 shares ($587K approx. pre-tax spread)
Exercise and Sale
12 txns
Insider
Selecky Christobel
Role
Director
Sold
96,722 shs ($871K)
Approx. gross sale proceeds
$871K
Approx. exercise cost
$284K
Approx. pre-tax spread
$587K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 700 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 300 | $0.00 | $0.00 |
| Exercise | Common Stock | 700 | $2.98 | $2K |
| Exercise | Common Stock | 300 | $2.99 | $897.00 |
| Sale | Common Stock | 1,000 | $9.00 | $9K |
| Exercise | Stock Option (right to buy) | 32,173 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 33,549 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 30,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 32,173 | $2.98 | $96K |
| Exercise | Common Stock | 33,549 | $2.99 | $100K |
| Exercise | Common Stock | 30,000 | $2.84 | $85K |
| Sale | Common Stock | 95,722 | $9.0075 | $862K |
Holdings After Transaction:
Stock Option (right to buy) — 292,264 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (2)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026.
- F2. Represents the weighted average share price of an aggregate total of 95,722 shares sold in the price range of $9.00 to $9.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Key Figures
Shares sold: 96,722 shares
Weighted-average sale price: $9.0075/share
Additional sale price: $9.00/share
+5 more
8 metrics
Shares sold
96,722 shares
Common Stock sold in open-market transactions on June 29–30, 2026
Weighted-average sale price
$9.0075/share
95,722-share block sale of Common Stock
Additional sale price
$9.00/share
1,000-share Common Stock sale on June 30, 2026
Options exercised
96,722 shares
Total Common Stock from option exercises (code M) in this filing
Exercise price 1
$2.84/share
Stock Option (right to buy) exercised; expires June 18, 2035
Exercise price 2
$2.99/share
Stock Option (right to buy) exercised; expires June 13, 2033
Exercise price 3
$2.98/share
Stock Option (right to buy) exercised; expires June 14, 2032
Net buy/sell direction
Net-sell of 96,722 shares
Transaction summary netBuySellShares and netBuySellDirection
Key Terms
Rule 10b5-1 trading plan, open-market sale, Stock Option (right to buy), derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action: "open-market sale" and transaction_code_description: "Sale in open market or private transaction""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)" with underlying security titled "Common Stock""
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Common Stock financial
"security_title: "Common Stock" used for both exercises and sales"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ImmunityBio (IBRX) director Christobel Selecky do in this Form 4?
Christobel Selecky exercised stock options and sold the resulting ImmunityBio shares. She exercised options for 96,722 Common Stock shares and sold 96,722 shares in open-market transactions disclosed in this Form 4 filing.
What option exercises did Christobel Selecky report for ImmunityBio (IBRX)?
She exercised stock options covering 96,722 shares of Common Stock at exercise prices of $2.84, $2.98, and $2.99 per share. These exercises converted derivative positions into common shares that were then sold.
Does Christobel Selecky still hold ImmunityBio (IBRX) Common Stock after these transactions?
After the reported transactions, she showed zero directly held Common Stock shares. However, she continued to hold stock options with remaining balances at the stated exercise prices and expiration dates.
What stock option positions remain for Christobel Selecky in ImmunityBio (IBRX)?
The filing shows remaining stock options including 132,786 shares at a $2.84 exercise price expiring June 18, 2035, 124,714 shares at $2.99 expiring June 13, 2033, and 35,764 shares at $2.98 expiring June 14, 2032.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates